Partnership Expands Access to Alzheimer’s Blood Tests in Latin America and Caribbean

Amyloid PET imaging can help identify brain amyloid pathology, a hallmark of Alzheimer’s disease, but infrastructure constraints may restrict its availability. As disease-modifying therapies begin to reshape Alzheimer’s care in parts of Latin America, scalable diagnostic tools are becoming increasingly important to support clinical evaluation and treatment pathways. A new collaboration now aims to broaden access to blood-based Alzheimer’s disease assessment across Latin America and the Caribbean.

C2N Diagnostics, LLC (St. Louis, MO, USA), a specialty diagnostics company focused on brain health, has announced a partnership with SouthGenetics (Miami, FL, USA), a diagnostics company with more than 20 years of experience introducing advanced molecular and precision medicine testing across Latin America and the Caribbean. Through the collaboration, healthcare professionals across the region will gain access to C2N’s Precivity portfolio of blood tests, which are designed to provide information related to amyloid pathology associated with Alzheimer’s disease. The alliance will initially focus on Argentina, Chile, Colombia, the Dominican Republic, Ecuador, Jamaica, Mexico, Uruguay, and Venezuela, with additional countries to be evaluated.

The Precivity blood tests are intended to aid healthcare professionals in detecting amyloid plaques in the brain and to help inform medical management and treatment decisions for appropriate patients undergoing evaluation for cognitive impairment or dementia. The tests are available only through qualified healthcare professionals and are intended to be used in conjunction with clinical assessment, rather than as standalone diagnostic tests for Alzheimer’s disease. C2N’s PrecivityAD2 blood test has been evaluated in clinical studies using plasma biomarkers, including p-tau217 and Aβ42/Aβ40 ratio, to identify Alzheimer’s disease pathology.

The partnership builds on C2N’s prior work supporting Alzheimer’s disease early-detection initiatives in Latin America and other global settings. C2N’s PrecivityAD test was included in the Davos Alzheimer’s Collaborative Healthcare System Preparedness Early Detection Flagship Program, which implemented digital cognitive assessments and blood biomarkers across sites in six countries, including Mexico and Brazil. Published findings from that program reported increased clinician confidence in diagnosing and managing cognitive impairment in primary care and non-specialty settings.

Under the collaboration, SouthGenetics will support regional implementation through its commercial, medical, and logistics network across Latin America and the Caribbean. The company will work to facilitate physician awareness, country-specific activation, sample logistics, and access pathways for patients undergoing evaluation. Together, the organizations aim to help bridge gaps in Alzheimer’s disease assessment by making advanced blood biomarker testing more accessible in countries where specialist capacity and amyloid PET imaging availability may be constrained.

“C2N’s Precivity portfolio is grounded in rigorous science and was developed to help health care professionals obtain a clearer picture of Alzheimer’s disease pathology,” said Dr. Joel Braunstein, President and CEO of C2N Diagnostics. “This partnership with SouthGenetics represents an important step in expanding access to advanced blood biomarker testing in countries where health systems are preparing for a new era of Alzheimer’s disease care.”

“For Latin America and the Caribbean, the challenge is not only scientific innovation — it is implementation,” said Washington Rodriguez, CEO of SouthGenetics. “Advanced diagnostics must be made accessible to health care professionals and patients through reliable logistics, medical education, and country-by-country execution. SouthGenetics was created to bridge that diagnostic divide, and we are proud to work with C2N to help bring the Precivity portfolio to the region.”